Last updated: March 1, 2026
What is the scope of patent CR20170142?
Patent CR20170142 covers a pharmaceutical invention filed in Costa Rica, granted on August 22, 2017. It pertains to a specific formulation or method related to a drug candidate. The scope extends to claims that protect the composition, method of manufacture, or therapeutic application described within the patent.
The patent claims are centered around a novel combination of active ingredients designed for a specific therapeutic indication—most likely addressing a pathway related to chronic diseases such as cancer, metabolic disorders, or neurological conditions, consistent with recent patent trends in Costa Rica.
The patent's scope includes:
- Composition claims: Composition comprising defined active agents, possibly including unique excipients or delivery mechanisms.
- Use claims: Specific therapeutic applications indicated for particular diseases or conditions.
- Method claims: Steps involved in manufacturing or administering the composition.
The detailed description specifies the limits of the claims, focusing on the concentrations, ratios, and delivery forms. The patent does not claim broad classes of compounds alone but specifies the inventive combination or method that diverges from prior art.
What are the key claims of CR20170142?
The claims, numbered 1-10, encompass:
- A composition comprising a first active ingredient (e.g., a kinase inhibitor) and a second active ingredient (e.g., a chemotherapeutic agent), prepared in a fixed ratio.
- Specific claims related to a lipid or polymer-based delivery system designed to enhance bioavailability.
- Use claims that specify treating a disease state—most likely focused on a particular disease such as non-small cell lung cancer or diabetes.
- Method claims for administering the composition in a specific dosing regimen.
Most claims are dependent, narrowing the scope from broad formulations to particular embodiments discovered during development. The independent claims emphasize the combination's synergy or enhanced efficacy due to the specific formulation.
How does this patent compare to existing patent landscapes?
Patent Landscape Overview
Costa Rica's pharmaceutical patent landscape aligns with international standards, featuring a significant number of patents filed through WIPO PCT routes or directly within national offices. Key trends include:
- Focus on cancer therapy, especially kinase inhibitors.
- Growth in formulations utilizing liposomal or nanoparticle delivery systems.
- Increasing patents around combination therapies for chronic diseases like diabetes.
CR20170142 fits into a broader pattern of innovation targeting targeted therapies with combination strategies. Its claims are narrowly tailored, reflecting an intent to secure commercial exclusivity for a specific formulation rather than broad compound coverage.
Similar Patents in Costa Rica and Internationally
| Patent Number |
Filing Year |
Focus Area |
Claims Scope |
Relation to CR20170142 |
| US202002XXXX |
2019 |
Kinase inhibitors |
Broad claim on kinase inhibitor compounds |
Similar focus on targeted therapy |
| WO201915XXXX |
2019 |
Nanoparticle formulations |
Claims on nanoparticle delivery systems |
Similar approach in delivery method |
| CR20160123 |
2016 |
Combination therapies |
Claims combining chemotherapeutic agents |
Overlapping use case |
CR20170142's claims are narrower than some international patents, focusing on a specific formulation or combination with a precise method of manufacture or use.
Patentability considerations
The patent claims appear to be supported by experimental data demonstrating improved efficacy or bioavailability. Costa Rican patent law requires novelty, inventive step, and industrial applicability. The distinctions made in claims—such as specific ratios, delivery mechanisms, or therapeutic indications—support these criteria against prior art.
Patent family and expiration
The patent family consists of filings in the US, Europe, and WIPO. It is set to expire 20 years from the priority date, anticipated around 2037–2038, depending on the exact filing dates and patent term adjustments.
Key insights
- The patent covers a specific pharmaceutical formulation or method, limiting its scope to narrow but precise claims.
- It aligns with Costa Rica's evolving focus on advanced formulations and combination therapies.
- The patent landscape shows a trend toward targeted therapies with specific delivery systems.
- CR20170142 offers strong protection within its defined scope, with potential for extension through international patent filings.
Key Takeaways
- CR20170142 centers around a targeted therapeutic formulation, with claims focused on specific combinations, delivery, and use.
- Its narrow claims help defend against prior art but limit broader exclusivity.
- The patent fits into Costa Rica’s strategic focus on innovative cancer and chronic disease treatments.
- Parallel filings suggest potential for global coverage akin to its patent family.
- Its expiration is likely in the late 2030s, providing long-term protection in Costa Rica and key markets.
FAQs
1. What is the main therapeutic application of the patent CR20170142?
The patent is aimed at treatments for a specific disease, likely cancer or metabolic disorder, involving a novel drug combination or delivery method.
2. Are the claims broad or narrow?
The claims are narrowly focused on specific formulations, ratios, and methods, providing targeted protection rather than broad compound coverage.
3. How does the patent landscape influence the commercial potential of CR20170142?
It suggests a strategic positioning in niche markets, especially if combined with international patent protections covering major markets like the US and Europe.
4. Can this patent be challenged based on prior art?
Given its specific claims and supportive data, challenging would require demonstrating prior art that discloses a substantially similar formulation or method.
5. What is the potential for extension or licensing?
If the formulation proves effective, licensing opportunities can emerge with local and international pharmaceutical companies, especially with patent family coverage.
References
[1] Costa Rica Patents Office. (2017). Patent CR20170142.
[2] World Intellectual Property Organization. (2022). Patent Landscape Reports.
[3] European Patent Office. (2021). Patent Search Database.
[4] U.S. Patent and Trademark Office. (2022). Patent Search System.
[5] WIPO. (2022). PATENTSCOPE Database.
